LiDCO (AIM: LID), the hemodynamic monitoring company, announces that following the notification in the Annual Report, on 20 April 2018, the Board finalised a grant of options ('Options') to Mr Sassone, CEO, to subscribe for new ordinary shares of 0.5p each ('Ordinary Shares').
Option type
Number of shares over which options granted
Total number of options held post grant
Percentage of issued share capital under option
Matt Sassone
Unapproved
1,000,000
4,147,342
1.70%
EMI
3,448,262
1.41%
Total
1,000,000
7,595,604
3.11%
The above Options vest and may be exercised three years from grant if certain share price hurdles are met. The Options are exercisable over a range of periods at 0.5 pence per Ordinary Share, subject to the Company's share price averaging above a number of hurdle rates. The expiry date is April 2023. The hurdle rates were set with regard to the closing midmarket price on Thursday 19 April and are between 8.38p and 12.38p.
Full details of these Options and others held are given in the Company's report and accounts (Directors' remuneration report) which are available on the Company's website.
The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Matt Sassone
2.
Reason for the notification
a)
Position/status:
Chief Executive Officer
b)
Initial notification/Amendment:
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name:
LiDCO Group Plc
b)
LEI:
213800PYQTIUV6HIYL36
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument:
Identification code:
Ordinary Shares of 0.5p nominal
GB0030546849
b)
Nature of the transaction:
Grant of Management Share Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
0.5p
1,000,000
d)
Aggregated information:
· Aggregated volume:
· Price:
Single transaction as in 4 c) above
Price(s)
Volume(s)
0.5p
7,595,604
e)
Date of the transaction:
20/04/18
f)
Place of the transaction:
London Stock Exchange, AIM (XLON)
For further information, please contact:
LiDCO Group Plc
www.lidco.com
Matt Sassone (CEO)
Tel: +44 (0)20 7749 1500
finnCap
Tel: +44 (0)20 7600 1658
Geoff Nash / Emily Watts (Corporate Finance)
Stephen Norcross (Corporate Broking)
Walbrook PR Ltd
Tel: 020 7933 8780 or lidco@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Lianne Cawthorne
Mob: 07584 391 303
Attachments
Original document
Permalink
Disclaimer
LIDCO Group plc published this content on 29 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 29 June 2018 06:33:10 UTC
Lidco Group Ltd, formerly LiDCO Group Plc, is a United Kingdom-based supplier of non-invasive and minimally invasive hemodynamic monitoring equipment to hospitals. The Company is engaged in the development, manufacture and sale of cardiac monitoring equipment. It operates in the segment of supply of monitors, consumables and support services associated with the use of its cardiac monitoring equipment. The Company's products include LiDCOplus, a computer-based platform monitor; LiDCOrapid, a cardiac output monitor; LiDCOview, a graphical display, and LiDCOunity, which is its hemodynamic monitor. Its LiDCOrapid is designed for multi-parameter monitoring of both depth of anesthesia and fluids. Its products are used in the treatment of high-risk patients in both critical care units and in the operating theatre. They monitor the amount of blood flowing around the body helping clinicians and nurses to ensure that organs are kept perfused with oxygenated blood.
LIDCO GROUP PLC 
